Sinopia Biosciences Inc (AKA: CHOmics Inc) Profile last edited on: 2/21/2022
CAGE: 6T1Y7
UEI: YAZGZHHKK821
Business Identifier: Enabling data-driven drug discovery utilizing multi-omics data, machine learning, network analyses, and disease models 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 50
County: San Diego
Congr. District: 50
County: San Diego
Public Profile
Currently resident in JLabs San Diego, and previously (until 2014) doing business as CHOmics, Inc, Sinopia Biosciences is structured around development of a bioinformatics platform designed for drug discovery and drug re-purposing. Using proprietary machine learning, the effort is to identify therapeutics that reduce adverse drug reactions of life-changing medications. Utilizing advanced computational approaches to identify new solutions that improve drug efficacy and safety. Addressing a lead compound employed in Parkinson's Disease, a focus is on enabling doctors to identify pathways that are implicated in causing Parkinson's Disease. With an impressive Phase I to Phase II converstion record in NIH - their only SBIR source - the firm has no recorded instance of capital investment - a fairly rare situation in most firms inthis arena.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $1,811,919 | |
| Project Title: Preclinical assessment of a novel compound for treating radiation-induced oral mucositis | ||||
| 2023 | 2 | NIH | $3,421,621 | |
| Project Title: Preclinical development of a novel therapeutic for Parkinson's disease | ||||
| 2022 | 2 | NIH | $2,650,011 | |
| Project Title: Development of a Metabolomics and Machine Learning Based High-Throughput Screening Platform for Data-Driven Drug Discovery | ||||
| 2020 | 2 | NIH | $1,747,650 | |
| Project Title: Developing a Systems Biology Platform for Predicting Drug Toxicity and Safety | ||||
| 2019 | 1 | NIH | $224,284 | |
| Project Title: Improving Safety and Efficacy of Platelet Pathogen Inactivation Techniques Through Systems Biology | ||||
Key People / Management
Aarash Bordbar -- Co-Founder
Iman Famili -- PresidentandCEO
Bernard Bloem
Colton Lloyd
Bernhard Palsson -- Co-Founder
Iman Famili -- PresidentandCEO
Bernard Bloem
Colton Lloyd
Bernhard Palsson -- Co-Founder
Company News
There are no news available.
